Ishihara H - Search Results

1

Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.

Ishihara H, Yamaguchi S, Nakao I, Okitsu A, Asahina S. Ishihara H, et al. Diabetes Obes Metab. 2016 Dec;18(12):1207-1216. doi: 10.1111/dom.12745. Epub 2016 Sep 15. Diabetes Obes Metab. 2016. PMID: 27436788 Free PMC article. Clinical Trial.

2

Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.

Otsuka Y, Yamaguchi S, Furukawa A, Kosuda M, Nakazaki M, Ishihara H. Otsuka Y, et al. Among authors: ishihara h. Endocr J. 2015;62(2):133-43. doi: 10.1507/endocrj.EJ14-0148. Epub 2014 Oct 19. Endocr J. 2015. PMID: 25328079 Free article. Clinical Trial.

3

Octreotide for hypoglycemia caused by sulfonylurea and DPP-4 inhibitor.

Yamaguchi S, Ikejima M, Furukawa A, Abe M, Nakazaki M, Ishihara H. Yamaguchi S, et al. Among authors: ishihara h. Diabetes Res Clin Pract. 2015 Aug;109(2):e8-e10. doi: 10.1016/j.diabres.2015.05.008. Epub 2015 May 12. Diabetes Res Clin Pract. 2015. PMID: 26025695

4

Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study.

Ishihara H, Yamaguchi S, Nakao I, Sakatani T. Ishihara H, et al. Diabetes Ther. 2018 Aug;9(4):1549-1567. doi: 10.1007/s13300-018-0455-8. Epub 2018 Jun 20. Diabetes Ther. 2018. PMID: 29926400 Free PMC article.

5

Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study.

Ishihara H, Yamaguchi S, Nakao I, Asahina S, Sakatani T. Ishihara H, et al. Diabetol Int. 2018 Jul 16;10(1):37-50. doi: 10.1007/s13340-018-0359-x. eCollection 2019 Jan. Diabetol Int. 2018. PMID: 30800562 Free PMC article.

6

Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy.

Ishihara H, Yamaguchi S, Sugitani T, Kosakai Y. Ishihara H, et al. Clin Drug Investig. 2019 Dec;39(12):1213-1221. doi: 10.1007/s40261-019-00851-z. Clin Drug Investig. 2019. PMID: 31552641 Free PMC article.

7

Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB).

Kitazawa T, Seino H, Ohashi H, Inazawa T, Inoue M, Ai M, Fujishiro M, Kuroda H, Yamada M, Anai M, Ishihara H. Kitazawa T, et al. Among authors: ishihara h. Diabetes Obes Metab. 2020 Sep;22(9):1659-1663. doi: 10.1111/dom.14059. Epub 2020 May 7. Diabetes Obes Metab. 2020. PMID: 32314464 Free PMC article. Clinical Trial.

8

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.

Koike M, Saito H, Kohno G, Takubo M, Watanabe K, Ishihara H. Koike M, et al. Among authors: ishihara h. Int J Mol Sci. 2021 Oct 25;22(21):11463. doi: 10.3390/ijms222111463. Int J Mol Sci. 2021. PMID: 34768897 Free PMC article.

9

Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study.

Watanabe K, Yamaguchi S, Kosakai Y, Ioji T, Ishihara H. Watanabe K, et al. Among authors: ishihara h. Clin Drug Investig. 2023 Dec;43(12):927-937. doi: 10.1007/s40261-023-01317-z. Epub 2023 Nov 7. Clin Drug Investig. 2023. PMID: 37934351

10

Dissipating excess energy stored in the liver is a potential treatment strategy for diabetes associated with obesity.

Ishigaki Y, Katagiri H, Yamada T, Ogihara T, Imai J, Uno K, Hasegawa Y, Gao J, Ishihara H, Shimosegawa T, Sakoda H, Asano T, Oka Y. Ishigaki Y, et al. Among authors: ishihara h. Diabetes. 2005 Feb;54(2):322-32. doi: 10.2337/diabetes.54.2.322. Diabetes. 2005. PMID: 15677488

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,502 results

Search Page